Sangamo Poised for Breakout with Forthcoming BLA Submission
AI Prediction of Sangamo Therapeutics, Inc. (SGMO)
Sangamo Therapeutics, a genomic medicine company, has shown significant potential despite recent challenges, including the termination of partnerships with Pfizer and Novartis. The company has a promising pipeline with a focus on neurology and genomic medicines, such as the ongoing STAAR study for Fabry Disease, which shows promise for accelerated approval. Sangamo's recent license agreements and potential upcoming submissions to regulatory bodies could act as catalysts for future growth. Investors should consider the company's high R&D investment and recent strategic partnerships, which may offset the risks associated with its past financial instability and partnership terminations.
SGMO Report Information
Prediction Date2025-07-03
Close @ Prediction$0.53
Mkt Cap74m
IPO DateN/a
AI-derived Information
Recent News for SGMO
- May 4, 10:30 am — BC-Most Active Stocks (Associated Press)
- Apr 30, 8:05 am — Sangamo Therapeutics to Present Pipeline and Technology Advances at the 29th Annual Meeting of The American Society of Gene & Cell Therapy (ASGCT) (GlobeNewswire)
- Apr 29, 10:45 am — Sangamo Therapeutics (SGMO) Nasdaq delisting shifts stock to OTCQB market (InvestorsHub)
- Apr 29, 10:30 am — BC-Most Active Stocks (Associated Press)
- Apr 29, 8:05 am — Sangamo Therapeutics Announces Transition to Trading on OTCQB Venture Market (GlobeNewswire)
- Mar 31, 8:30 am — Sangamo Therapeutics, Inc. Q4 2025 Earnings Call Summary (Moby)
- Mar 30, 11:01 pm — Sangamo Therapeutics Inc (SGMO) Q4 2025 Earnings Call Highlights: Strategic Advances and ... (GuruFocus.com)
- Mar 30, 4:19 pm — Sangamo: Q4 Earnings Snapshot (Associated Press)
- Mar 30, 4:01 pm — Sangamo Therapeutics Reports Recent Business Highlights And Fourth Quarter And Full Year 2025 Financial Results (GlobeNewswire)
- Mar 19, 4:03 pm — Sangamo Therapeutics Announces Fourth Quarter and Full Year 2025 Earnings Call (GlobeNewswire)
- Mar 9, 8:05 am — Sangamo Therapeutics Advances Rolling Submission of BLA to U.S. FDA for ST-920 in Fabry Disease (GlobeNewswire)
- Feb 3, 4:05 pm — Sangamo Therapeutics Presents Detailed Data from Registrational STAAR Study in Fabry Disease at WORLDSymposium 2026 (GlobeNewswire)
Welcome to ScanScor. What you're reading is no ordinary summary -- it's the result of a carefully-crafted interactive session with OpenAI's most advanced models crafted from news, trial details, and financial data. This report attempts to maximize the potential for OpenAI's smartest GPT-based analysis engine, guided by tightly structured prompts to expose the forces behind today's market movers and to predict the future.
Disclaimer: This report is for informational purposes only. It does not constitute financial advice. Always do your own research before making any investment.
Thesis State: BROKEN
Do not revive the old prediction.
Do not update the old target.
Create a separate post-StateBreak / OTC event-watch note only if you want to track it.
I would classify this as:
For your actual long position: I’d treat it as a discipline test, not a ScanScor-approved trade.
Personally, I would not average in. I would define the trade as either:
1. Tiny speculative event trade into ASGCT
Hold only if you are comfortable with OTC volatility and have a clear exit before or around May 12–15.
This prediction is still feasible in thesis terms, but much less feasible at the original $4.50 target.
The is simple: the core bullish catalyst is still alive. Sangamo has continued the rolling BLA submission for ST-920 in Fabry disease, first announcing the rolling submission in December 2025 and then stating on March 9, 2026 that it had now submitted the preclinical and clinical modules to the FDA for review. That means the prediction’s main premise was not broken; it actually progressed.
But the market has not rewarded that progress yet. The stock is now around the mid-$0.30s to low-$0.40s, below the $0.53 prediction-date close, with market cap still only about $120M–$125M. So for SGMO to hit $4.50 from here, it would need something closer to a 10x–13x move from recent trading levels, not merely the original 754% move from July. That is a very high bar unless there is a major repricing event such as decisive regulatory validation, a strong partnership, or a genuine squeeze/speculation wave.